In the following video, Motley Fool health care analyst David Williamson takes investors through Eli Lilly's mixed quarter. Though the company faces some big near-term difficulties owing to it stepping off a huge patent cliff this quarter, it managed to beat analysts' expectations, which drove shares up 4%. David discusses how the company was able to beat this quarter, just how much its patent cliff hurt, and what we can expect from the company this year.
